

# Asian Journal of Animal and Veterinary Advances



www.academicjournals.com

Asian Journal of Animal and Veterinary Advances 10 (8): 394-405, 2015 ISSN 1683-9919 / DOI: 10.3923/ajava.2015.394.405 © 2015 Academic Journals Inc.



# Sequence Characterization of Baculoviral Inhibitor of Apoptosis Repeat Containing 5 (*BIRC* 5) Gene from a Case of Canine Mammary Tumour

<sup>1</sup>Subas Chandra Jena, <sup>1</sup>Sonal Saxena, <sup>1</sup>Sameer Shrivastava, <sup>1</sup>Manoj Kumar, <sup>2</sup>Monalisa Sahoo, <sup>1</sup>Priyanka Sharma, <sup>1</sup>Saumya Shrivastava, <sup>3</sup>Naveen Kumar, <sup>3</sup>Swapan Kumar Maiti and <sup>1</sup>Bishnu Prasad Mishra

<sup>1</sup>Division of Veterinary Biotechnology, Indian Veterinary Research Institute, Izatnagar, Bareilly, Uttar Predash, India

<sup>2</sup>Division of Veterinary Pathology, Indian Veterinary Research Institute, Izatnagar, Bareilly, Uttar Predash, India

<sup>3</sup>Division of Veterinary Surgery, Indian Veterinary Research Institute, Izatnagar, Bareilly, Uttar Predash, India

Corresponding Author: Sonal Saxena, Division of Veterinary Biotechnology, Indian Veterinary Research Institute, Izatnagar, Bareilly, Uttar Predash, India

# ABSTRACT

The BIRC 5 (also called survivin), member of the inhibitor of apoptosis protein family is highly over-expressed in human and animal cancers leading to poor prognosis. Still there is limited information about the gene sequence in dogs suffering with canine mammary tumour. Therefore, the present study was undertaken to find out any correlation of BIRC 5 gene over-expression with mutation status of the gene. The CMT tissues were confirmed by histopathological examination and included cases of mixed myoepithelioma, complex adenocarcinoma, mixed mammary capillary cystic adenocarcinoma and invasive solid carcinoma etc. Quantitative Real Time PCR (gRT-PCR) revealed  $5.6\pm0.462$ - $60.0\pm1.476$  fold higher BIRC 5 gene expression levels in CMT tissues as compared to dog normal mammary gland tissues. The coding region of the gene was amplified, cloned and sequenced from a case of complex mammary carcinoma showing approximately  $60.0\pm1.476$  fold amplification of BIRC 5 gene. The sequence showed 100% similarity with the mRNA sequences of normal dog BIRC 5 present in NCBI. This indicates that BIRC 5 gene sequence in healthy dogs is similar to dogs suffering from CMT and showing over-expression of the gene. The multiple sequence alignment of the survivin gene with other species like cat, cow, buffalo, sheep, goat and human etc. revealed more than 90% similarity. The phylogenetic analysis demonstrates that gene is highly conserved across species to maintain its functional integrity. The findings revealed that there is no sequence alteration in BIRC 5 gene sequence in the CMT tissue showing more than 60 fold over-expression of the gene.

Key words: BIRC 5, survivin, canine mammary tumour, sequence characterization

# INTRODUCTION

Incidence of cancer, resulting from complex interactions between environmental and genetic factors has increased alarmingly in the recent years (Pharoah *et al.*, 2004; Wang *et al.*, 2012). Alterations in many cancer related genes are highly correlated with drastic changes in the gene

expression (Masica and Karchin, 2011). Such type of alterations, affecting gene expression levels can be used to identify driver genes and molecular subtypes of a particular cancer (Verhaak *et al.*, 2010; Noushmehr *et al.*, 2010).

Canine Mammary Tumours (CMTs) are the most common malignancy of female dogs of more than 5 years of age (Davidson, 2003; Murphy, 2008; Salas *et al.*, 2015) accounting for more than 40% of all tumours diagnosed (Sleeckx *et al.*, 2011; Beck *et al.*, 2013). Majority of canine mammary tumours have poor clinical outcome with thrice higher mortality rates than human breast cancer (Egenvall *et al.*, 2005; Shafiee *et al.*, 2013). Chemotherapy, radiation therapy and surgery are the principal therapeutic strategies available to treat malignant CMTs (Queiroga *et al.*, 2011). However, not a single chemotherapy protocol has been reported to be effective in management of malignant CMTs (Simon *et al.*, 2006; Kumar *et al.*, 2010). Further, there is increased risk of recurrence or metastasis, within 2 years following mastectomy (Rutteman and Misdorp, 1993; MacEwen and Withrow, 1996). Thus canine mammary tumour being a severe neoplastic condition of dogs can be considered as a promising candidate for development of strategies for disease management.

Baculoviral inhibitor of apoptosis repeat containing 5 (BIRC 5), also called as survivin is a smallest member of Inhibitors of Apoptosis Protein (IAP) family. The gene is present on chromosome 17 q25 in humans (Ambrosini et al., 1998). It is highly over-expressed in human and animal cancers leading to poor prognosis. Amplification of the BIRC 5 gene has been reported in vast majority of cancers including oesophageal, lungs, ovarian, central nervous system, breast, colorectal, bladder, gastric, prostate, pancreatic, laryngeal, uterine, hepatocellular and renal cancers (Altieri, 2003; El-Magd et al., 2012). Over expression of this gene is associated with tumour progression and malignancy (Altieri, 2006) and is considered as an unfavourable prognostic marker of cancer in humans (Tango et al., 2010; Bongiovanni et al., 2015). The survivin protein contributes to genesis of cancers by acting as negative regulator of apoptosis or programmed cell death. The targeted disruption of survivin induction pathways leads to increased apoptosis and decreased tumour growth (Blanc-Brude et al., 2003; Uchida et al., 2004; Tao et al., 2012). Apart from tumours, the protein is highly expressed in embryonic and foetal tissues, but is completely absent in terminally differentiated adult cells (Chang et al., 2004; Lechler et al., 2007; Xue et al., 2012; Jaiswal et al., 2015). The survivin expression in embryonic and foetal development contributes to tissue homeostasis and differentiation (Adida et al., 1998; ElSheikh et al., 2014). Survivin expression is highly regulated by the cell cycle and the protein is only expressed in the G2-M phase (Altieri, 2008; Jaiswal et al., 2015). The aberrations in the developmental pathways results in prominent re-expression of survivin during neoplasia. These data suggest that survivin might provide a new target for cancer therapy that would discriminate between transformed and normal cells. However, the exact mechanism of apoptosis inhibition by survivin is yet poorly understood and still there is limited information about the gene sequence in the canine mammary tumours tissues. Therefore, the present study was taken up to analyze whether survivin gene sequence is altered in dogs suffering from CMT and showing over expression of the survivin gene.

## MATERIALS AND METHODS

**Ethical statement:** The study was carried out after approval from the Institute Animal Ethics Committee (IAEC) of Indian Veterinary Research Institute (IVRI), Izatnagar, Bareilly, UP, India.

**Tumour tissues:** The CMT tissues used in the study were obtained after surgical removal of tumours from clinical cases of CMTs presented to the "Referral Veterinary Polyclinic", Indian

Veterinary Research Institute (IVRI), Izatnagar, Bareilly, India. Histological examination and classification of spontaneous mammary tumours from dogs was performed on H and E stained tissue sections according to World Health Organization (WHO) criteria for CMTs (Misdorp *et al.*, 1999).

**RNA isolation and cDNA synthesis:** Total RNA was extracted from tissue samples by RNeasy<sup>TM</sup> mini kit (Qiagen, Hilden, Germany) as per the manufacturer's instructions. The integrity of the isolated RNA was conformed after agarose gel electrophoresis of the sample on 1.5% agarose gel. The purity of RNA was assessed by calculating  $OD_{260}/OD_{280}$  using Nanodrop (NanoDrop1000, Thermo Scientific, Singapore). Subsequently, an in solution DNase digestion step (RNase free DNase I, MBI Fermetas USA) was performed to remove genomic DNA contamination. The cDNA was then prepared from total RNA using Revert Aid cDNA synthesis kit (Fermentas, USA) as per the manufacturer's instructions. The cDNA from each tumour sample was synthesized using Oligo (dT) 18 primers and 1 µg total RNA in a total volume of 20 µL and incubated at 65°C for 5 min, 42°C for 60 min followed by final incubation at 70°C for 5 min. The prepared cDNA was stored at -80°C for downstream applications.

**Real time quantitative PCR:** Survivin mRNA expression was assayed by real time PCR using Applied Biosystems<sup>®</sup> 7500 fast real time PCR instrument. A set of intron-spanning primer sequences for dog survivin were designed using Premier 5.0 software (National Bioscience) and analyzed using oligoanalyzer 3.1. To normalize the amount of input RNA or cDNA, *RPS* 19 gene was selected as an endogenous control. Reaction was performed using KAPA SYBR FAST qPCR master mix (KAPA Biosystems, Boston, MA, USA) according to the manufacturer's instructions. Briefly, 10 µL of the reaction mixture, consisting of 5 µL SYBR FAST qPCR master mix, 0.4 µL cDNA and 200 nmol L<sup>-1</sup> of forward and reverse primers was subjected to initial denaturation at 95°C for 3 min followed by 40 cycles of denaturation at 95°C for 3 sec and annealing/extension at 60°C for 20 sec. The relative gene expression levels were determined using the  $2^{-\Delta\Delta Ct}$  method (Schmittgen and Livak, 2008). All mRNA expression levels were normalized to those of normal mammary tissues obtained from dog post mortem cases. Data was expressed as the mean values calculated from experiments performed in triplicate. The specificities of the PCR amplicons were confirmed using melting curve analysis.

Survivin gene amplification, cloning and sequence analysis: Primers for amplification of full length survivin were designed using DNA star laser gene v6 software from the published sequence (NCBI accession number NM\_001003348.1) and custom synthesized by Integrated DNA technologies (USA). Sites for restriction enzymes Bam HI and Hind III were incorporated to the 5' ends of forward and reverse primer, respectively. The cDNA from a case of complex mammary carcinoma showing over expression of survivin gene was used as a template for amplification of survivin gene. The cycling conditions for amplification of the gene included, initial denaturation at 95°C for 5 min, followed by 35 cycles of denaturation at 98°C for 20 sec, annealing at 60°C for 15 sec and extension at 72°C for 15 sec with final extension at 72°C for 10 min. The PCR was performed in a 50  $\mu$ L reaction mixture containing 25  $\mu$ L KAPA hi-fidelity PCR master mix (2X), 0.5  $\mu$ L of 20 pM each of forward and reverse primer and 3  $\mu$ L of template cDNA. The amplified PCR product was purified using Qiagen MinElute<sup>®</sup> PCR purification kit as per the manufacturer's

instructions. The purified product was subjected to R.E. digestion using BamHI and HindIII restriction endonucleases (NEB, England) at 37°C for 2 h. The pET-32b (+) vector was also subjected to RE digestion with Bam HI and Hind III to generate complementary overhangs. The digested vector and the PCR product were then subjected to overnight ligation at 4°C using T4 DNA ligase (Promega, Madison, USA). The ligated product was subsequently transformed into *E. coli* DH5*a* competent cells. The recombinant clones were screened by colony PCR. The recombinant plasmid was purified from the overnight grown culture using PureYield<sup>TM</sup> plasmid miniprep system (Promega) and subjected to RE digestion using *Bam* HI and *Hind* III restriction endonucleases for further confirmation of the recombaint clone. The recombinant plasmid by sequencing at Eurofins Genomics India Pvt Ltd (Bangalore, India). The gene sequence was analyzed and compared to homology with other survivin gene sequences present in the data bases using DNASTAR's MegAlign sequence alignment software, Blastn (Basic Local Alignment Search Tool) and NCBI. The phylogenetic analysis was done using MEGA6 software.

## RESULTS

**Gross and histopathological examination of CMT tissues:** CMT tissues were collected from clinical cases of dogs which were referred for surgery to "Referral Veterinary polyclinics" Indian Veterinary Research Institute, Izatnagar. The photographs showing gross appearance of some representative tumour masses from CMT cases are shown in Fig. 1. The tumour tissues collected from surgically operated tumour masses were fixed in 10% neutral buffered formalin and H and E staining of the formalin fixed tissue sections was done for histopathological analysis as shown in Fig. 2. Based on the histopathological examination, tumour tissues were classified as shown in Table 1.



Fig. 1(a-d): Gross appearance of representative canine mammary tumour tissues collected from surgically operated cases of CMTs, (a, b, c and d) represents different CMT cases



Fig. 2(a-d): Histopathological examination (H and E staining) of some of the representative canine mammary tumour tissues, (a) Intraductal adenocarcinoma, (b) Carcinosarcoma, (c) Complex carcinoma and (d) Invasive solid carcinoma

Table 1: Classification of some of the representative CMT tissues based upon the histopathological findings

Tumour classification Mixed myoepithelioma Complex adenocarcinoma Complex carcinoma Carcinosarcoma Mixed mammary capillary cystic adenocarcinoma Invasive solid carcinoma

Survivin expression in canine mammary tumours vs normal tissues by real time PCR: The concentration of RNA isolated from the mammary tissues ranged from 80-200 ng  $\mu$ L<sup>-1</sup>. On agarose gel electrophoresis two distinct bands corresponding to 28 S and 18 S rRNA were observed. The OD<sub>260/280</sub> was found to be~1.9 indicating good purity of the RNA samples. The cDNA's synthesized from the tumour tissues were used for analysis of *BIRC* 5 gene over-expression by quantitative real time PCR (qPCR). The amplification curves for the real time PCR analysis are illustrated in Fig. 3a. Single and sharply defined melting curves with narrow peaks were obtained showing specificity of real-time PCR amplification (Fig. 3b). Overexpression of *survivin* gene was detected in 6 out of 8 (75%) mammary tumour tissues examined. The samples from CMT cases showed 5.6±0.462- 60.0±1.476 fold higher expression levels of the gene as compared to normal mammary gland tissue (Fig. 4).

**Survivin gene amplification, cloning and sequence analysis:** The PCR amplification of the *BIRC* 5 gene from a case of complex carcinoma showing over-expression of the gene was performed as described earlier. The amplified product showed expected band size of 516 bp on agarose gel electrophoresis (Fig. 5). The amplified product was cloned in pET-32b (+) vector and the recombinants were analyzed by RE digestion and further confirmed by plasmid DNA sequencing. Restriction digestion of the recombinant plasmid pET-32b (+) *survivin* with *Bam* HI and *Hind* III





Fig. 3(a-b): Amplification and dissociation curves for Survivin gene (a) Amplification plot and (b) Melt curve (Dissociation curve)



Fig. 4: Relative expression of survivin in different CMT tissues represented as CMT1-CMT8



Fig. 5: PCR amplified survivin gene in 1.5% agarose gel. L: 100 bp DNA ladder, Lane 1: Survivin amplified PCR product Lane 2: NTC-No template control

released the insert of 516 bp (Fig. 6). The recombinant plasmid was purified and sent for sequencing. The gene sequence was analyzed and compared for homology with other survivin gene



Fig. 6: Restriction analysis for confirmation of recombinant pET 32b (+) Survivin plasmid.
Restriction digestion of recombinant pET32b (+) Survivin plasmid with Bam HI and Hind III showing the insert (Survivin) release. L: 1 kb DNA ladder, Lane 1: Insert release (Survivin) marked by arrow, Lane 2: Undigested recombinant plasmid

00	GATTTGAATCGO	<b>BECACCOCTCOR</b>	CGTOGCOK	PC99C99GAT9	BEFECCEST	TOG TIGOCOCO	CORCTORCA	RETETACCTCA	AGGACCACCO	OFFETETACC	TTCAAGAA	CIGOCCCTTC	Majority
	10 20	30	40	50	60	70	80	90	100	110	120	130	
	T T	1	1	00000000000	-	in the second	-	Longer Longer	10000000000	Secondia di	TRODALGAN	-	Bog taumus (NYCOCOLA 1) and
	CONTRACTOR	ann-anacarana	····	COOLATO	22222-11021	00 2700000	CORCETTORICA/	CTCTACCTCA	AGGACCACCO	ALC: CONCEACY	TTCALGAL	TOOCCHITC	Canin familiaris(2V741504.1).cer
TCO	OGTTTGAATCOO	SCC-GOSCTCTG	C TOTOOCOX	COCCOGATO	BBBCBCTTCOT	TOG CTGCCCC	COGCCTOGCA	CTCTACCTCA.	AOGACCACCO	GTCTCTAOF	TTCAAGAA	CTOSCOUTTC	Canis lupus familiaris(CMT TISSUE).seg
TCG	OGTTTGAATCOO	acc-sesercres	C TOTOGCOX	COOCOOGATO	BORCOCTTON	CE CTGCCCC	COGOCTOGCA	SCTCTACCTCA.	AGGACCACCO	GTCTCTACG	TTCAAGAA	CTOGCCOTTC	Canis lupus familiaris(NM 001003348.1).
·····	GATTTGAATCOR	anciacocretia	cBorffocox	TOTCOOGATO	BBBCBCTTCGT	100 1100000	COGCCTOGCA	OCTOTACOTCA.	AGGACCACOG	ATCTCTACG	TTCAAGAA	CTOGCCOTTC	Felis catus(NM 001009280.1).seq
	COGAATTCO	33GACCCOTTOS	CAGAGOTOGCOX	COOCOOCATO	sostoccocca	03 77300000	CPGCCTGGCA	SCOCTTTCTCA.	AGGACCACCOK	ATCTCTACA	TTCAAGAA	CTGGCCCTTC	Homo sapiens(HM625836.1).seq
AACCOCCO	GATTTGAATCOO	BOCACCOCTCOO	c 00000K	C000AT0	300TOCCAOT	CT TTGCCTC	COGCCTOGCA	CTCTACCTCA.	AGGACCACCOK	OTCTOUACA	TTTAAGAA	CTOOCCUTTC	PREDICTED Bubalus bubalis (XM 006064105.
00	GATTTGAATCOO	BREACCOCTORS	T 0000X	CASCOOGATO	30010000000	CA TIOCCCC	CHACCTORCA:	JETCTACCTCA.	AGGACCACCO	TCTORACE	TTTAAGAA	CTOSCOUTIC	PREDICTED Camelus dromedaries(XM 010983
AACCOCCO	GATTIGAATOGO	BOCACTOCTORS	c 0000X	C OOGATO	300TOCCA/0T	CC TTRCCCC	COGCCTGGCA	SCTCTACCTCA.	AGGACCATOR	GICTORACO	TTEAAGAA	CT09000 TTC	PREDICTED Capra hircus(XM 005694094.1).
AACCOCCO	GATTTGAATCGO	30CA 9CGCTC99	c00000	COGGATO	3330030000031	CG TIGCCCC	CAGOCTOGCA	<b>SCIUTATCICA</b>	AGGACCACOG	GICTCTACC	TTCAAGAA	CTGGCCUTTC	PREDICTED Equus caballus(XM 001915400.3
	-ATTTGAATCGO	GGGACCOUTIGG	CAGAGOTGGCCK	2000COOR ATO	sourceate	CA TOCCCC	CIGCOTGGCA	SCHOTHEOTCA	AGGACCACCG	ATCICIACA	TTCAAGAA	croscente	PREDICTED Macaca nemestrina(XM 01172005
AACCUCCO	GATTIGAATCOD	SUCARCOCTCDO	C	ACTAR BOOMATO	333130222401	CO Proceed	CUACCIOGCA	SCICIACOICA	ASGACCACCO	GICIORACO	1112443444	citoocourie	PREDICTED OVIS aries musimon(XM 0121095
TTOGAGOO	CTGCGCCTGCAC	CCCGGAGCGGAT	99CCGA99CC9	CTTCATCCAC	CTUTCCCACTO	AG AACGAGC	COGACTTOGO	CASTOTTICT	TCTOCTTCAAG	GAGCTOGAA	OOCTOOGA	CCAGATGAC	Majority
14	0 150	160	170	180	190	200	210	222	220	240	250	200	
14	0 150	100	170	- 100	190	200	210	220	230	240	250	260	
TOGAGOG	CTGCGCCTGCAC	CCCAGAGOGGAT	GGCDGAGGCCG(	<b>TTCATCCAC</b>	CTGCCCACTG	BAG AACGAGC	COGATTTOGC	CASIGITICI	INTOCTICAAG	GAGCTOGAA	OGCTGOGA(	RCCAGATGA	Bos taurus(AY606044.1).seq
CTGGAGGG	CTGCGCCTGCAC	CCCGGACCGGAT	GGCAGAGGCCGK	CTTCATCCAC	CTGTOCCACTO	TAG AACGAGO	CAGACTIGGO	CAGIGITICT	ICTOCTTCAA0	GAGCTOGAA	GOCTOOGA(	RCCAGATGAT	Canis familiaris(AY741504.1).seq
CTOGA000	CTGCGCCTGCAC	CCCGGGACCOGAT	99CAGA999CCOK	CTTCATCCAC	CTGTCCCACTO	AG AACGAGC	CAGACTTOGC	CASTGTTTCT	<b>PCTGCTTCAAG</b>	GAGCTOGAA	OGCTOOGA	RCCAGATGAT	Canis lupus familiaris(CMT TISSUE).seq
CTOGAGGG	CTGCGCCTGCAO	CCCGGACCOGAT	99CAGA999CCOK	REFECATOCAC	CIGICCCACIC	JAG AACGAGCI	CAGACITOGC	CASIGITICT	ICTOCTTCAA0	KAGCTOKIAA	OUCTOOGAC	ACCAGATGAT	Canis lupus familiaris(NM 001003348.1).
TIGGAGGG	CIGCOCCIGCAC	CCCGGAGCOGAT	00000400000	REFECATOCAC	CIGICOCACIO	AGAAQGAGG	CHOMPTOOC	CASIGITICT	ICIGCITCAAL	KIAGCTOKIAA	00CT000AL	ACCAGADUAT	Felis Catus(NM 001009280.1).seq
1002000	C1000000100A0	000000000000000000000000000000000000000	~~~~~~	SCIICAICCAL	CIONCIC	100 2200200	and an and a state	CARDONNER	DODOCTOCA NO	Ch	00000000	COLORATION OF	ppptctpp pubalus bubalis(YM 006064105
10000	cracocorraca	000000000000000000000000000000000000000	22772222222	CTTOCATOCAC	CIGICCCACIO	12/2 22/072/00	TRACTING	CAGINGTITICT	D'DOCTROAN	CAGOTOGA &	200000000000000000000000000000000000000	COCAGA COLA	PREDICTED Camelus dromedaries(XM 010983
1000000	CTGCGCCTGCAC	000000000000000000000000000000000000000	2000000000	CTTCATOCAC	CTOTOCOCACTO	LAG AACGAGO	COGACTTOOC	CAOTOTTTCT	TCTOCTTCAAO	GAGETOGAA	OCTOOGA	CCAGAGOAC	PREDICTED Capra hircus(XM 005694094.1).
1000000	cracaccracad	TOCOGRAGOOGAT	200000000000000000000000000000000000000	CTTCATCCAC	TOTOCACTO	AACGAOCI	CORTTAGO	CASTOTTICT	PCTGCTTCAA0	GAGCTOGAA	OOCTOOOA	CCAGATGAC	PREDICTED Equus caballus (XM 001915400.3
TOGAOOO	CTGCGCCTGCAC	CCCOGGAGCOGAT	0000034000070	CTTCATCCAC	CTOROCCACTO	AG AACGAGO	CAGACTTOGC	CASTGTTTCT	ICTOCTTCAA0	GAGCTOGAA	OCTOOGA	CONGATGAC	PREDICTED Macaca nemestrina (XM 01172005
TAGAGOG	CTGCGCCTGCAC	CCCGGAGCGGAT	9900090990000	CTTCATCCAC	CTUTOCCACTO	AG AATGAGO	COACTTOOC	CAGTGTTTCT	ICTOCTTCAAG	GAGITOGAA	ascreaul	CCAGATGAC	PREDICTED Ovis aries musimon(XM 0121095
								-					Madaniau
GACCOTA	ГАЗАЗЗАСАТАЛ 1	AAAGCATTCATC	TOSTISTOT	TOCTTTCTGT	CAAGAAGCAG	TTGAAGAAT	тадоостско	IGAATTTTTGA	чстозасала	GAAAGAGCCA	YGAACAAA	ATTOCAAAG	Majority
GACCCTAT 270	14949944CATAJ 280	AAAGCATTCATC 290	TOGTTOTOCTT 300	310	220	TTTGAAGAAT	тадоостсая 340	150 350 3	400 3	GAAAGAGCCA 70 3	1400	ATTOCAAAG 390	Majority
GACCOTAT 270 GACCOTAT	280 280	290 AAAGCATTCATC	TOGTTOTOCTT 300	310	244G44GCAG1 320 CAAGAAGCAG7	777 GAAGAAT	TAACCCTCAG 340 TAACCCTCAG	150 2 100000000000000000000000000000000000	4000 3	GUUIGLOCCA 70 3 GUUIGLOCCA	4342044	ATTOCAAAG 390 ATTOCAAAG	Majority Bos taurus(AY606044.1).seg
GACCOTAT 270 GACCOGAT GACCOTAT	TAGAGGAACATAJ 280 TAGAGGAACATAJ TAGAGGAGCATAJ	290 290 AAAACATTCATC	300 SOUTOTOCTT	310 Teerretate	CAAGAAGCAGT 320 CAAGAAGCAGT CAAGAAGCAGT	TTTGAAGAAT 33 TTTGAAGAAT	TAACOCTCAG 340 TAACOCTCAG TAACOCTCAG	IGAATTITTGA 350 3 IGAATTITTGA IGAATTITTGA	40000000000000000000000000000000000000	аллалосся 70 3 аллаласся аллаласся	AGAACAAA	ATT9CAAAG 390 ATT9CAAAG ATT9CAAAG	Majority Bos taurus(AY606044.1).seq Canis familiaris(AY741504.1).seq
GACCOTAT 270 GACCOTAT GACCOTAT GACCOTAT	TAGAGGAACATAJ 280 TAGAJGAACATAJ TAGAGGAGGAGCATAJ TAGAGGAGGAGCATAJ	290 290 MAARCATTCATC MAAACATTCATC MAAACATTCATC	TOSTTOTOCTT 300 DOSTTOTOCTT TOSTTOTOCTT TOSTTOTOCTT	310 TCCTTICTOR TCCTTICTOR TCCTTICTOR	224334333333 320 24434433333240 2443443243333240 24434432433	TTT GAAGAAT 33 TTT GAAGAAT TTT GAAGAAT	TRACOCTORG 340 TRACOCTORG TRACOCTORG TRACOCTORG	IGAATTTTTGA 350 3 IGAATTTTTGA IGAATTTTTGA IGAATTTTTGA	4CT9GACAAA 60 3 4ACT9GACAAA 4ACT9GACAAA	GAAAGAGCCA     T	180 100 100 100 100 100 100 100 100 100	ATTGCAAAG 390 ATTGCAAAG ATTGCAAAG ATTGCAAAG	Majority Bos taurus(AY606044.1).seq Canis familaris(AY741504.1).seq Canis lupus familaris(AFT TISSUE).seq
GACCOTA 270 GACCOTA GACCOTA GACCOTA GACCOTA	TAGAGGAACATAJ 280 TAGAJGAACATAJ TAGAGGAGCATAJ TAGAGGAGCATAJ TAGAGGAGCATAJ	290 290 AAAACATTCATC AAAACATTCATC AAAACATTCATC	TOGTTOTOCTT 300 TOOTTOTOCTT TOOTTOTOCTT TOOTTOTOCTT TOOTTOTOCTT	TCCTTTCTGTC 310 TCCTTTCTGTC TCCTTTCTGTC TCCTTTCTGTC TCCTTTCTGTC	СААЗААЗСАЯ 320 СААЗААЗСАЯ СААЗААЗСАЯ СААЗААЗСАЯ СААЗААЗСАЯ	ГТТ GAAGAAT 33 ГТТ GAAGAAT ГТТ GAAGAAT ГТТ GAAGAAT ГТТ GAAGAAT	TRACOCTORS 340 TRACOCTORS TRACOCTORS TRACOCTORS TRACOCTORS	04477777640 350 2 204477777040 204477777040 204477777040 204477777040	истозасала 60 3 истозасала истозасала истозасала истозасала истозасала	GAAAGAGCCA 70 3 GAAAGAGCCA GAAAGAGCCA GAAAGAGCCA GAAAGAGCCA	180 180 1408ACAAA 1408ACAAA 1408ACAAA 1408ACAAA	ATTOCAAAG 390 ATTOCAAAG ATTOCAAAG ATTOCAAAG ATTOCAAAG	Majority Bos taurus(AY606044.1).seq Canis familiaris(AY741504.1).seq Canis lupus familiaris(MY T15508).seq Canis lupus familiaris(MY 01000348.1).
GACCCTA1 270 0ACCCTA2 GACCCTA2 GACCCTA2 GACCCTA2 GACCCTA2 GACCCTA2	TAGAGGAACATAI 280 TAGANGAICATAI TAGAGGAGCATAI TAGAGGAGCATAI TAGAGGAGCATAI TAGAGGAGCATAI	AAAAGCATTCATC 290 AAAACATTCATC AAAACATTCATC AAAACATTCATC AAAACATTCATC	TOGETOTOCTT 300 BOOTTOTOCTT TOGETOTOCTT TOGETOTOCTT TOGETOTOCTT TOGETOTOCTT	allo contractors recontractors recontractors recontractors recontractors recontractors recontractors	CAAGAAGCAGT 320 CAAGAAGCAGT CAAGAAGCAGT CAAGAAGCAGT CAAGAAGCAGT CAAGAAGCAGT	ПТ ЗААЗААТ 33: ПТ ЗААЗААТ ПТ ЗААЗААТ ПТ ЗААЗААТ ПТ ЗААЗААТ ПТ ЗААЗААТ	TRACOCTORS 340 TRACOCTORS TRACOCTORS TRACOCTORS TRACOCTORS TRACOCTORS	IGAATTITIGA 350 2 DIAATTITIGA DIAATTITIGA DIAATTITIGA DIAATTITIGA DIAATTITIGA	истозасала 60 3 истозасала истозасала истозасала истозасала истозасала истозасала	GUARANCEA 70 3 GUARANCEA GUARANCEA GUARANCEA GUARANCEA GUARANCEA GUARANCEA	AGALCAA 180 JAGALCAAA JAGALCAAA JAGALCAAA JAGALCAAA	ATTOCAAAG 390 ATTOCAAAG ATTOCAAAG ATTOCAAAG ATTOCAAAG ATTOCAAAG	Majority Bos taurus(AY606044.1).seq Canis familiaris(AY741504.1).seq Canis lupus familiaris(GMT 71850E).seq Canis lupus familiaris(GMT 00100348.1). Palis catus(GMT 00100348.1).seq
GACCCTA1 270 1 GACCCTA3 GACCCTA3 GACCCTA3 GACCCTA3 GACCCTA3 GACCCTA3	TAGAGGAACATAJ 280 TAGAAGAA CATAJ TAGAGGAACATAJ TAGAGGAGCATAJ TAGAGGAACATAJ TAGAGGAA CATAJ	AAAGCATTCATC 290 AAAACCATTCATC AAAACCATTCATC AAAACCATTCATC AAAACCATTCATC AAAACCATTCATC	TOGETOTOCTT 300 TOGETOTOCTT TOGETOTOCTT TOGETOTOCTT TOGETOTOCTT TOGETOTOCTT	TCCTTTCTGTC 310 TCCTTTCTGTC TCCTTTCTGTC TCCTTTCTGTC TCCTTTCTGTC TCCTTTCTGTC TCCTTTCTGTC	CAAGAAGCAG 320 CAAGAAGCAG CAAGAAGCAG CAAGAAGCAG CAAGAAGCAG CAAGAAGCAG CAAGAAGCAG	TTT GAAGAAT 33: TTT GAAGAAT TTT GAAGAAT TTT GAAGAAT TTT GAAGAAT TTT GAAGAAT	TRACCCTCAG 340 TRACCCTCAG TRACCCTCAG TRACCCTCAG TRACCCTCAG TRACCCTCAG TRACCCTCAG TRACCCTCAG	IGAATTITITIGA 350 2 DIAATTITIGA DIAATTITIGA DIAATTITIGA DIAATTITIGA DIAATTITIGA DIAATTITIGA	4 60 3 4 4 3 4 4 3 4 4 3 4 4 3 4 4 3 3 3 4 4 5 4 4 5 4 4 5 4 5 4 5 4 5 4 5 4 5 4 5 4 5 4 5 4 5 4 5 4 5 4 5 4 5 4 5 4 5 4 5 4 5 4 5 5 5 5 5 5 5 5 5 5 5 5 5	анналасся 70 3 анналасся анналасся анналасся анналасся анналасся анналасся анналасся	чалсал чалсал чалсал чалсал чалсал чалсал чалсал чалсал чалсал чалсал чалсал чалсал чалсал чалсал чалсал чалсал чалсал чалсал чалсал чал чал чал чал чал чал чал ч	ATTOCAAAG 390 ATTOCAAAG ATTOCAAAG ATTOCAAAG ATTOCAAAG ATTOCAAAG	Majority Bos taurus(AY606044.1).seq Camis familiaris(AY741504.1).seq Camis lupus familiaris(MY O1003348.1). Felis catus(BM 00100280.1).seq Komo aşpians(B625364.1).seq
GACCCTAN           1           270           1           GACCCTAN	TAGAGGAACATAJ 280 TAGAAGAA CATAJ FAGAGGAGCATAJ FAGAGGAGCATAJ FAGAGGAACATAJ FAGAGGAA CATAJ FAGAGGAA CATAJ	AAAGCATTCATC 290 AAAACCATTCATC AAAACCATTCATC AAAACCATTCATC AAAACCATTCATC AAAACCATTCATC AAAACCATTCATC	TOSTTOTOCTT 300 TOSTTOTOCTT TOSTTOTOCTT TOSTTOTOCTT TOSTTOTOCTT TOSTTOTOCTT TOSTTOTOCTT TOSTTOTOCTT	a lo a lo corrector corrector corrector formerso formerso formerso formerso formerso formerso formerso	СААGААЗСАЯ 320 СААGААЗСАЯ СААGААЗСАЯ СААGААЗСАЯ СААGААЗСАЯ СААGААЗСАЯ СААGААЗСАЯ СААGААЗСАЯ СААGААЗСАЯ	PTT GAAGAAT 33' PTT GAAGAAT PTT GAAGAAT PTT GAAGAAT PTT GAAGAAT PTT GAAGAAT PTT GAAGAAT	TRACCCTCR/F 340 TRACCCTCR/F TRACCCTCR/F TRACCCTCR/F TRACCCTCR/F TRACCCTCR/F TRACCCTCR/F TRACCCTCR/F	AAATTITIGA 350 2 DAAATTITIGA DAATTITIGA DAATTITIGA DAATTITIGA DAATTITIGA DAATTITIGA	ACTORACIAA ACTORACIAA ACTORACIAA ACTORACIAA ACTORACIAA ACTORACIAA ACTORACIAA ACTORACIAA ACTORACIAA ACTORACIAA	анлалосся 70 3 анлаласся анлаласся анлаласся анлаласся анлаласся анлаласся анлаласся анлаласся		ATTOCAAAG 390 ATTOCAAAG ATTOCAAAG ATTOCAAAG ATTOCAAAG ATTOCAAAG ATTOCAAAG ATTOCAAAG	Majority Bos taurus(AY606044.1).seq Camis function (AY743504.1).seq Camis lupus familiaris(OMT TISUUS.seq Camis lupus familiaris(DM 00100338.1). Pélis catus(DM 0010038.0.1).seq Romo angiens(DM653516.1).seq ESDICTETE Dubulus bubalis(CM 06064105.
GACCCTAI     1     270     0     0     ACCCTAI     GACCCTAI     GACCCTAI     GACCCTAI     GACCCTAI     GACCCTAI     GACCCTAI     GACCCTAI     GACCCTAI     GACCCTAI	EAGAGGAACATAU 280 FAGAAGGAACATAU FAGAGGAGCATAU FAGAGGAACATAU FAGAGGAACATAU FAGAGGAACATAU FAGAGGAACATAU	ARAGGATTCATC 290 ARACATTCATC ARACATTCATC ARACATTCATC ARACATTCATC ARACATTCATC ARACATTCATC ARACCATTCATC ARACCATTCATC	TOSTTOTOCTT 300 TOSTTOTOCTT TOSTTOTOCTT TOSTTOTOCTT TOSTTOTOCTT TOSTTOTOCTT TOSTTOTOCTT TOSTTOTOCTT	a 10 Teerrretore reerrretore reerrretore reerrretore reerrretore reerrretore reerrretore reerrretore reerrretore reerrretore reerrretore reerretore r	CAAGAAGCAG 320 CAAGAAGCAG CAAGAAGCAG CAAGAAGCAG CAAGAAGCAG CAAGAAGCAG CAAGAAGCAG CAAGAAGCAG CAAGAAGCAG CAAGAAGCAG	TT GAAGAAT 3.3 TT GAAGAAT TT GAAGAAT TT GAAGAAT TT GAAGAAT TT GAAGAAT TT GAAGAAT TT GAAGAAT	ТАЛОСТСИЯ 340 ТАЛОСТСИЯ ТАЛОСТСИЯ ТАЛОСТСИЯ ТАЛОСТСИЯ ТАЛОСТСИЯ ТАЛОСТСИЯ ТАЛОСТСИЯ ТАЛОСТСИЯ ТАЛОСТСИЯ ТАЛОСТСИЯ	CONTINUES	44CT958C244 460 3 44CT958C244	аналалосса 70 3 аналалосса аналалосса аналалосса аналалосса аналалосса аналалосса аналалосса аналалосса аналалосса		ATTOCAAAG 390 ATTOCAAAG ATTOCAAAG ATTOCAAAG ATTOCAAAG ATTOCAAAG ATTOCAAAG ATTOCAAAG	Majority Eom taurus(AY606044.1).seq Camis fupus familiaris(AYT150UT).seq Camis lupus familiaris(AYT150UT).seq Camis Jupus familiaris(AYT150UT).seq Komo aspiane(B0655614.1).seq FMEDICTED SubAlus hubalis(CM 00604103. FMEDICTED SubAlus Accession 2000.000000000000000000000000000000000
GACCCTAI     1     270     0     0     COLOR     GACCCTAI	280 280 70000000000000000000000000000000			rectriction all rectriction rectriction rectriction rectriction rectriction rectriction rectriction rectriction rectriction	СААДААССКОТ 1 320 СААДААССКОТ	TTT GAAGAAT 1 33: 1 0 AAGAAT TTT GAAGAAT TTT GAAGAAT TTT GAAGAAT TTT GAAGAAT TTT GAAGAAT TTT GAAGAAT TTT GAAGAAT	ТАЛОСТСИЯ 340 ТАЛОСТСИЯ ТАЛОСТСИЯ ТАЛОСТСИЯ ТАЛОСТСИЯ ТАЛОСТСИЯ ТАЛОСТСИЯ ТАЛОСТСИЯ ТАЛОСТСИЯ ТАЛОСТСИЯ ТАЛОСТСИЯ	аза 2 350 2	астоасыя настоасыя настоасыя настоасыя настоасыя настоасыя настоасыя настоасыя настоасыя настоасыя настоасыя настоасыя	анлалоса 70 3 анлалоса анлалоса анлалоса анлалоса анлалоса анлалоса анлалоса анлалоса анлалоса анлалоса анлалоса		ATTOCAAAG 390 ATTOCAAAG ATTOCAAAG ATTOCAAAG ATTOCAAAG ATTOCAAAG ATTOCAAAG ATTOCAAAG ATTOCAAAG ATTOCAAAG	Majority Ene faurus(AY006044.1).seq Canis fupus familiaris(MY 7150UD).seq Canis lupus familiaris(MY 01003340.1). Pélis catus(MN 001003280.1).seq Momo angiens(M8053816.1).seq PEDICTTE Camelus bubbals(CM 004064105. PEDICTTE Camelus bubbals(CM 004064105.) PEDICTTE Camelus donosdaries(DM 010981) PEDICTTE Camelus donosdaries(DM 010981)
GACCCTRA           1           270           GACCCTRA	EX5003AACATAU 2 80 EX000 (DAI (CATA) EX0003A0CATA) EX0003A0CATAJ EX0003A0CATAJ EX0003A0CATAJ EX0003A0CATAJ EX0003A0CATAJ EX0003A0CATAJ EX0003A0CATAJ	ARAGCATTCATC 290 URAN CATTCATC URAN CATTCATC URAN CATTCATC URAN CATTCATC URAN CATTCATC URAN CATTCATC URAN CATTCATC URAN CATTCATC		rectriction in a second second rectriction rectriction rectriction rectriction rectriction rectriction rectriction rectriction rectriction rectriction	СААСААССКАТ Т Т СААСААССКАТ СААСААССКАТ СААСААССКАТ СААСААССКАТ СААСААССКАТ СААСААССКАТ СААСААССКАТ СААСААССКАТ СААСААССКАТ СААСААССКАТ СААСААССКАТ СААСААССКАТ СААСААССКАТ СААСААССКАТ	TTT GAAGAAT 1 33: 1 1 1 1 1 1 1 1 1 1 1 1 1	ТРАСССТСИЯ 340 ТРАСССТСИЯ ТРАСССТСИЯ ТРАСССТСИЯ ТРАСССТСИЯ ТРАСССТСИЯ ТРАСССТСИЯ ТРАСССТСИЯ ТРАСССТСИЯ ТРАСССТСИЯ ТРАСССТСИЯ ТРАСССТСИЯ	350         2           350         2           00047171704         2           00447171704         2           00447171704         2           00447171704         2           00447171704         2           00447171704         2           00447171704         2           00447171704         2           00447171704         2           00447171704         2           00447171704         2           00447171704         2	истоянский (60 3) истоянский истоянски	Comparison of the second		ATTISCAAAG 390 ATTISCAAAG ATTISCAAAG ATTISCAAAG ATTISCAAAG ATTISCAAAG ATTISCAAAG ATTISCAAAG ATTISCAAAG	Majority Eos taurus(AY606044.1).seq Camis funga familiaris(AY715201).seq Camis lupus familiaris(AY7152010).seq Camis lupus familiaris(AY 10003144.1). Mono aspiran(B0653561.1).seq PREDICTED Eukalus hubalıs(DM 06664104.1). PREDICTED Capra hircus(DM 06564404.1). PREDICTED Capra hircus(DM 06564404.1).
GACCCTPA'           1           270           GACCCCTPA'           GACCCTPA'	28003AACATAU 280 1 280 1 28003AOCATAU 28003AOCATAU 28003AOCATAU 28003AOCATAU 28003AOCATAU 28003AOCATAU 28003AOCATAU 28003AOCATAU 28003AOCATAU	ЗАЛОСАТТСАТС 290 ЗАЛОСАТТСАТС ЗАЛОСАТТСАТС ЗАЛОСАТТСАТС ЗАЛОСАТТСАТС ЗАЛОСАТТСАТС ЗАЛОСАТТСАТС ЗАЛОСАТТСАТС ЗАЛОСАТТСАТС ЗАЛОСАТТСАТС		rectrictory rectrictory rectrictory rectrictory rectrictory rectrictory rectrictory rectrictory rectrictory rectrictory rectrictory rectrictory rectrictory rectrictory rectrictory rectrictory	Санданасскот т т санданасскот санданасск	TTT GAAGAAT TTT GAAGAAT TTT GAAGAAT TTT GAAGAAT TTT GAAGAAT TTT GAAGAAT TTT GAAGAAT TTT GAAGAAT TTT GAAGAAT TTT GAAGAAT	ТААСССТСЯ/7 ТААСССТСЯ/7 ТААСССТСЯ/7 ТААСССТСЯ/7 ТААСССТСЯ/7 ТААСССТСЯ/7 ТААСССТСЯ/7 ТААСССТСЯ/7 ТААСССТСЯ/7 ТААСССТСЯ/7 ТААСССТСЯ/7 ТААСССТСЯ/7 ТААСССТСЯ/7 ТААСССТСЯ/7 ТААСССТСЯ/7	350         3           1004717104         3           1004717104         3           1004717104         3           1004717104         3           1004717104         3           1004717104         3           1004717104         3           1004717104         3           1004717104         3           1004717104         3           1004717104         3           1004717104         3           1004717104         3	истозасана области и истозасана истоза	Comparison of the second	UGALCHA I III IIII IIII IIIII IIIIII IIIIII	ATTOCAAAG 390 ATTOCAAAG ATTOCAAAG ATTOCAAAG ATTOCAAAG ATTOCAAAG ATTOCAAAG ATTOCAAAG ATTOCAAAG ATTOCAAAG	Majority Ene taurus(AY006044.1).seq Canis Jupus Enuliaris(MY TISUUS.seq Canis Jupus Enuliaris(IMY 01003340.1). Felic catus(IM) 001003280.1).seq Momo angiens(IM053516.1).seq FEDICTTE Dualus bubbls(CMY 004064105. FEDICTTE Canelus dromedarise(IMY 010983 FEDICTTE Canelus dromedarise(IMY 010983 FEDICTED Equa caballus(IMY 01813140.5) FEDICTED Equa caballus(IMY 01813140.5) FEDICTED Equa caballus(IMY 01813140.5) FEDICTED Equa caballus(IMY 01813140.5) FEDICITED Equa caballus(IMY 01813140.5)
GACCCTA1           270           GACCCTA1	200 200 200 200 200 200 200 200 200 200	290 IAAA CATTCATC AAAA CATTCATC AAAA CATTCATC IAAA CATTCATC IAAA CATTCATC IAAA CATTCATC IAAA CATTCATC IAAA CATTCATC IAAA CATTCATC IAAA CATTCATC IIAA CATTCATC		COTTICISM COTTICISM COTTICISM COTTICISM COTTICISM COTTICISM COTTICISM COTTICISM COTTICISM COTTICISM COTTICISM COTTICISM COTTICISM	СААДААССИЛ 1 220 1320 140	TTT GAAGAAT TTT GAAGAAT	ТААСССТСЯ/ ТААСССТСЯ/ ТААСССТСЯ/ ТААСССТСЯ/ ТААСССТСЯ/ ТААСССТСЯ/ ТААСССТСЯ/ ТААСССТСЯ/ ТААСССТСЯ/ ТААСССТСЯ/ ТААСССТСЯ/ ТААСССТСЯ/ ТААСССТСЯ/ ТААСССТСЯ/ ТААСССТСЯ/ ТААСССТСЯ/ ТААСССТСЯ/ ТААСССТСЯ/		частозасная 	аналалоса 70 3 аналалоса	HIGHCHA 10 10 10 10 10 10 10 10 10 10	аттослала з90 аттослала аттослала аттослала аттослала аттослала аттослала аттослала аттослала аттослала аттослала аттослала аттослала аттослала аттослала аттослала аттослала аттослала аттослала	Majority Bos taurus(XY606044.1).seq Camis fupus familiaris(XYTTSSUUS.seq Camis lupus familiaris(XYTTSSUUS.seq Camis lupus familiaris(XYTTSSUUS.seq PREDICTED BubAlus bubAls(XYTO000544010. PREDICTED Capra hircus(XYT000544004.1). PREDICTED Capra hircus(XYT005440404.1). PREDICTED Capra hircus(XYT005440404.1). PREDICTED Capra hircus(XYT005440404.1). PREDICTED Capra hircus(XYT005440404.1).
GACCCTA1     270     GACCTA1     GACTA1     GACTA1     GACTA1     GACTA1     GACTA1	PRAROBARCATAU 2 8 0 FROM ON CATAU PRAROBORICATAU PRAROBORICATAU PRAROBORICATAU PROMOSAICATAU PROMOSAICATAU PROMOSAICATAU PROMOSAICATAU PROMOSAICATAU CATANOCROM	290 290 ЗАЛАСАТТСАТС ЗАЛАСАТТСАТС ЗАЛАСАТТСАТС ЗАЛАСАТТСАТС ЗАЛАСАТТСАТС ЗАЛАСАТТСАТС ЗАЛАСАТТСАТС ЗАЛАСАТТСАТС ЗАЛАСАТТСАТС ЗАЛАСАТТСАТС ЗАЛАСАТТСАТС			СААДААССИЛ Т Т СААДААССИЛ СААДАССИЛ СААДАСИЛ СААДАССИЛ СААДАССИЛ СААДАССИЛ СААДАССИЛ СААДАССИЛ СААДАССИЛ СААДАССИЛ СААДАССИЛ СААДАССИЛ СААДАССИЛ СААДАСИЛ СААДАССИЛ СААДАССИЛ СААДАССИЛ СААДАСИЛ СААД	гтт аллаллт ттт аллаллт гтт аллаллт гтт аллаллт гтт аллаллт гтт аллаллт гтт аллалт гтт аллалт	TAACCCTCAR TAACCCTCAR TAACCCTCAR TAACCCTCAR TAACCCTCAR TAACCCTCAR TAACCCTCAR TAACCCTCAR TAACCCTCAR TAACCCTCAR TAACCCTCAR TAACCCTCAR TAACCCTCAR		астоялсала (0 3 мстоялсала настоялса настоя	GAAAGAGCCA     TO     GAAAGAGCCA     GAAGGCAAGCCA     GAAGGCAAGGC		ATTOCAAAG ATTOCAAAG ATTOCAAAG ATTOCAAAG ATTOCAAAG ATTOCAAAG ATTOCAAAG ATTOCAAAG ATTOCAAAG ATTOCAAAG ATTOCAAAG ATTOCAAAG ATTOCAAAG ATTOCAAAG	Najority Ene taurus(AY006044.1).seq Canis Jupus Eamliaris(MY TISUUS.seq Canis Jupus Eamliaris(MY TISUUS.seq Canis Jupus Eamliaris(MY 00003340.1). Pelis catus(MN 00100326.1).seq RHODICTUS Dukulus bubalis(CM 004064105. PREDICTUS Canelus dromedarise(DM 010981 PREDICTUS Degus caballus(DM 00191340.3) PREDICTUS Degus caballus(DM 00191340.3)
GACCCTA'     270     GACCCTA'	280 280 10000000000000000000000000000000					ттт балбалат ттт балбалат ста балбалат ттт балбалат ста балбалат ста балбалат ста балбалат	TRACCOLOGIC TRACCO		астоянсии (60 3) истоянсии истоянси истоянси истоянси истоянсии истоянсии истоя	GAAAGAGCCA     TO 3     GAAAGAGCCA     GAAGAGCCA     GAAGAGCACA     GAAGAGCACA     GAAGAGCACA     GAA		аттослая эр аттослая	Majority Bos taurus(AY606044.1).seq Camis fugus familiaris(AYT15041).seq Camis fugus familiaris(AYT15040).seq Camis fugus familiaris(AYT15040).seq Magnetic fugus familiaris(AYT16040). PREDICTED Bubalus hubalis(AYT0604010). PREDICTED Capra hircus(AYT06040401). PREDICTED Oxis ahalius (AYT0604104001). PREDICTED Macaca memetrina(AYT0112005) PREDICTED Socia and and antimismo(AYT0112005) Najority
GACCCTA1           270           GACCCTA1           GAC	EXAMONANCE TABLE     2 80     2 80     EXAMPLE AN ANTALE     EXAMPLE      EXAMPLE					TTT GAAGAAT TTT GAAGAAT GAG GOOCTU GOO	TRACCCTCAST           140           TRACCCTCAST           TRACCTCAST           TRACTCAST           TRACTAST           TRACTAST           TRACTAST           TRACTAST           TRACTCAST		астроянская (0 3) (0 1000 салана (0 1000 с	аналанасся алаланасся аналанасся аналанасся аналанасся аналанасся аналана аналанася аналан		аттослаю аттослаю	Najority Ene taurus(AYG06044.1).seq Canis Jupus Eamliaris(AYT41504.1).seq Canis Jupus Eamliaris(AYT150UE).seq Canis Jupus Eamliaris(AYT150UE).seq Rhom samjens(HM625816.1).seq RHDDICTED Cambus bubalis(CM 006064105. PHEDICTED Cambus bubalis(
GACCCTRI           270           GACCCDAI           GACCCTAI           GAACCCAIA           GAACCCAIA           GAACCCAIA	28000000000000000000000000000000000000				Санданоскої 1 20 1 20 1 20 1 20 1 20 1 20 2 20		ТААСССТСАЯТ 1 340 ТААСССТСАЯТ ТААСССТСАЯТ ТААСССТСАЯТ ТААСССТСАЯТ ТААСССТСАЯТ ТААСССТСАЯТ ТААСССТСАЯТ 1 1 1 1 1 1 1 1 1 1 1 1 1	налатттана за странатта палаттата палатата пала пал		GAAAGAGCS           70         3           GAAAGACCS         3           GAAAGACS         3		аттэслая эро аттэслая	Majority Bos taurus(AY606044.1).seq Camis fupus familiaris(AYTAISOUT).eeq Camis lupus familiaris(AYTAISOUT).eeq Paris catus(DM 00100548.0).seq Paris catus(DM 00100548.0).seq PAREDICTED Excluse domedaris(AY 00105480.0). PAREDICTED Capra hircuc(AM 005548048.1). PAREDICTED Capra hircuc(AM 005548048.1). PAREDICTED Capra hircuc(AM 00155480.0). PAREDICTED Macaca memestrina(AM 0117005 PAREDICTED Macaca memestrina(AM 0117005) PAREDICTED Macaca memerta Macaca Maca
GACCCTAI           1           270           GACCCTAI           GAACCCTAI           GAACCCTAI           GAACCCTAI           GAAACCAA           400           GAAACCAA           GAAACCAA		ВАНОСКТТСКТ 290 ЗАЛА САТТСКТС НАЛАСКТТСКТС НАЛАСКТТСКТС НАЛАСКТТСКТС НАЛАСКТТСКТС НАЛОСКТСКТС НАЛОСКТСКТСКТС НАЛОСКТСКТС НАЛОСКТСКТС НАЛОСКТСКТС НАЛОСКТСКТС НАЛОСКТСКТС НАЛОСКТСКТС НАЛОСКТСКТС НАЛОСКТСКТС НАЛОСКТСКТС НАЛОСКТСКТСКТС НАЛОСКТСКТСКТС НАЛОСКТСКТСКТС НАЛОСКТСКТСКТС НАЛОСКТСКТСКТСКТС НАЛОСКТСКТСКТСКТС НАЛОСКТСКТСКТС НАЛОСКТСКТСКТСКТС НАЛОСКТСКТСКТСКТС НАЛОСКТСКТСКТС НАЛОСКТСКТС НАЛОСКТСКТС НАЛОСКТСКТС НАЛОСКТСКТСКТС НАЛОСКТСКТСКТС НАЛОСКТСКТСКТССКТССКТСКТС НАЛОСКТСКТСКТСКТССКТСКТССКТССКТССКТСКТСКТССКТСКТ			Санданаская 100 100 100 100 100 100 100 10	ITT GAAGBAT I I I I I I I I I I I I I	TRACCCTCAST           1           340           TRACCCTCAST           TRACCTCAST           TRACCTTONST           TRACCTCAST           TRACCTTONST           TRACCTTONST           TRACCTTONST           TRACCTTONST           TRACCTTONST           TRACCTTONST           TRACCTTONST           TRACCTTONST           TRACCTTONST			аналалосса паналалосса аналосса аналос		аттэсалад зэр аттэсалад	Majority Ese taurus(AYG06044.1).seq Camis fupus Eselliaris(GYT7150UD, seq Camis fupus Eselliaris(GYT7150UD, seq Camis fupus Eselliaris(GYT7150UD, seq Memo aspiens(GK05516.1).seq FMEDICTED Subalus hubalus(CM 00604100, FMEDICTED Subalus domedaris(GM 001091 SMEDICTED Eselua domedaris(GM 0010915000) FMEDICTED Eselua caballus(CM 001915000) FMEDICTED Eselua caballus(CM 00191500) FMEDICTED Eselua caballus(CM 00191500) FMED
GACCCTA!           270           GACCCGA!           GACCCTA!           GAACCCA!           GAAACCAA           GAAACCAA					23423AGCA07 320 CRADAGCA0 CRADAGCA07 C	РТТ ЗААЗААТ 1 3 3 3 1 1 1 3 3 1 1 1 3 3 3 1 1 3 3 1 1 3 3 1 1 3 3 1 1 3 3 1 1 1 3 3 1 1 1 3 3 1 1 1 3 3 1 1 1 3 1 3 1 1 1 3 1 3 1 1 1 3 1 3 1 1 1 3 1 3 1 1 1 3 1 3 1 1 1 3 1 3 1 1 1 3 1 3 1 1 1 3 1 3 1 1 1 3 1 3 1 1 1 3 1 3 1 1 1 3 1 3 1 1 1 3 1 3 1 1 1 3 1 3 1 1 1 1 3 1 3 1 1 1 1 3 1 3 1 1 1 1 3 1 3 1 1 1 1 3 1 3 1 1 1 1 1 3 1 3 1 1 1 1 3 1 1 1 1 1 1 1 1 1 1 1 1 1	TAACCOTCAST           1           340           TAACCOTCAST			аналанасся 70 3 аналанасся аналанасся аналанасся аналанасся аналанастя		аттослая аттос	Majority Bos taurus(AY606044.1).seq Camis fupus familiaris(XYT15504).seq Camis lupus familiaris(XYT15504).seq Camis lupus familiaris(XYT15504).seq PREDICTED Exhalus bubalis(XY 006064104. PREDICTED Capra hirous(XY 005684049.1). PREDICTED Capra hirous(XY 005684049.1). PREDICTED Capra hirous(XY 005684049.1). PREDICTED Macaca memetrina(XX 01172005 PREDICTED Macaca memetrina(XX 01172005 PREDICTED Macaca memetrina(XX 01172005 Majority Bos taurus(AY606044.1).seq Camis Lupus familiaris(XYT41504.1).seq
GACCCTA:           270           GACCCTA:           GACCCAA:           GAACCCAA:           GAACCCAA:           GAACCCAA:           GAAACCAA           GAAACCAA           GAAACCAA				тесттетити з о песттетити тесттети тесттети	CALEARAGAN 3 2 0 CHARAGONT CHA	тт алаант 1 1 1 1 1 1 1 1 1 1 1 1 1	TAACOCTOAD      TAACOCTOAD			GRAAGAGCS     TO 3     GRAAGAGCC     GRAAGAGCCC     GRAAGAGCCCC     GRAAGAGCCCC     GRAAGAGCCCC     GRAAGAGCCCC     GRAAGAGCCCC     GRAAGAGCCCC     GRAAGAGCCCC     GRAAGAGCCCCC     GRAAGAGCCCC     GRAAGAGCCCCC     GRAAGAGCCCCC		аттослая эро аттослая	Majority Ese taurus(AYG06044.1).seq Camis Jupa Eselliaris(ATT TISUUS.seq Camis Jupa Eselliaris(ATT TISUUS.seq Camis Jupa Eselliaris(ATT TISUUS.seq PREDICTO Eselliaris(ATT ASSAULT). PREDICTO Eselliaris(ATT ASSAULT). PREDICTO Capra hiruus(DN 006644041.1). PREDICTO Capra hiruus(DN 00157205 PREDICTO Ovis arise musimon(DN 0117205 PREDICTO Ovis arise musimon(DN 0121095 Majority Bos taurus(AYG06044.1).seq Camis Jupa familiaris(CMT 71550E).seq Camis Jupa familiaris(CMT 71550E).seq
GACCCTAI           270           GACCCTAI           GAACCCAIA           GAACCCAIA           GAACCCAIA           GAAACCAA           GAAACCAA           GAAACCAA           GAAACCAA	240 240 240 2000,000,000,000,000 2000,000,000,000,			Control of the second sec	САЛАВААССКО 320 САЛАВАСКА САЛ	тт алланат 33. 14. 15. 14. 14. 14. 14. 14. 14. 14. 14						аттослая аттос	Majority Bos taurus(AY606044.1).seq Camis fupus familiaris(XTTISUUS.seq Camis lupus familiaris(XTTISUUS.seq Densitiaris(XTTISUUS.seq Densitiaris(XTTISUUS.seq Densitiaris(XTTISUS.seq Densitiaris(XTTISUS.seq DEDICTED Capra hirous(XTISUS.Seq DEDICTED Capra hirous(XTISUS.Seq Canis lupus familiaris(XTISUS.seq Canis Augus familiaris(XTISUS.seq Canis lupus familiaris(XTISUS.seq Canis familiaris(XTISUS.se
GACCCTA:           270           GACCCTA:           GAACCCTA:           GAACCCA:           GAAACCA:           GAAACCA:           GAAACCA:           GAAACCA:           GAAACCA:							TAACOCTOAST     TAACOCTOA					АТТОСАНАЯ зо аттосаная Аттоса	Majority Ess taurus(AYG06044.1).seq Camis Jupas familiaris(AYT41504.1).seq Camis Jupas familiaris(AYT415007.seq Camis Jupas familiaris(AYT 115007.seq Magnetic Ayton (Magnetic Ayton) PREDICTED Essential discontinues PREDICTED Essential discontinues PREDICTED Capra hircus(AY 006064410.1). PREDICTED Capra hircus(AY 006064410.1).seq Camis Jupas familiaris(AYT 115007.seq Camis Jupas familiaris(AYT 115007.seq Camis Jupas familiaris(AYT 115077.seq Camis Jupas familiaris(AYT 115077.seq) Ayton AYT 115077.seq Camis Jupas familiaris(AYT 115077.seq Camis Jupas familiaris(AYT 115077.seq) Ayton AYTON AY
GACCCTA:           270           GACCCTA:           GAACCTA:           GAACCAA				CONTROLOGY     C		тт аллалат ттт алланат ттт аланат ттт аланат ттт алланат ттт алланат ттт алланат ттт алланат ттт алланат ттт аланат ттт аланат ттт аланат ттт аланат ттт аланат ттт аланат ттт аланат ттт аланат тттт аланат тттт аланат тттт аланат тттт аланат тттт аланат тттт аланаттттттт ттттттттттт ттттттттттттттт						АТТОСАНА З 10 З	Majority Bos taurus(AY606044.1).seq Camis fupus familiaris(XTT158UE).seq Camis fupus familiaris(XTT158UE).seq Table catus(MK 0010038.0.1).seq Momo asquark(MK01586.1).seq Momo asquark(MK01586.1).seq Momo asquark(MK01586.1).seq PEDICITE Capra hirouc(XM 00584004.1). PEDICITE Oscia ansmetrina(XM 01172005 PEDICITE Macaca nemetrina(XM 01172005 PEDICITE Macaca memetrina(XM 01172005 PEDICITE Macaca nemetrina(XM 01172005 Majority Bos taurus(AY606044.1).seq Canis fupus familiaris(XT 1050E).seq Canis fupus familiaris(XT 1050E).seq Pelis catus(MK 0200260.1).seq Pelis catus(MK 0200260.1).seq Pelis catus(MK 0200260.1).seq PEDICITE Oscia habita (MK 0200760.1).seq PEDICITE Oscia habita (MK 0200760.1).seq PEDICITE Oscia habita (MK 0200760.1).seq PEDICITE Oscia habita habita (MK 0100740.5).
GACCCTA:           270           GACCCTA:           GACCCCTA:           GACCCTA:           GACCCCTA:           GACCCCTA:           GACCCTA:           GACCCCTA:           GACCCCTA:           GACCCCTA:           GACCCCTA:           GACCCCTA:           GAACCCA:           GAACCCA:           GAACCA:           GAACCA:           GAAACCA:           GAAACCA:           GAAACCA:           GAAACCA:           GAAACCA:           GAAACCA:           GAAACCA:           GAAACCA:				Control of the second sec									Majority Bos taurus (XY606044.1).seq Camis lupus familiaris(XYT15504.1).seq Camis lupus familiaris(XYT155007.seq Camis lupus familiaris(XYT155007.seq PREDICTED Esubalus hubalis(XY 066646105. PREDICTED Capra hircus(XY 065646104.1). PREDICTED Capra hircus(XY 065646104.1). PREDICTED Capra hircus(XY 065646104.1). PREDICTED Macase nemestrian(XY 0515460.3). PREDICTED Macase nemestrian(XY 0515460.3). PREDICTED Macase nemestrian(XY 0515460.3). PREDICTED Capra hircus(XY 051540.3).seq Camis familiaris(XY 05160.1).seq Camis familiaris(XY 15050.3).seq Camis lupus familiaris(XY 15050.3).seq Camis lupus familiaris(XY 15050.3).seq Camis lupus familiaris(XY 15050.3).seq PREDICTED Fubalus hubalis(XY 060664.1).
GACCCTA:           270           GACCCTA:           GAACCCA:           GAACCCA:           GAACCCA:           GAAACCA:							TAROCITOAR           340           TRACCITOAR           TRACITOAR           TRACITOAR<						Majority Bos taurus (AY606044.1).seq Camis fupus familiaris(XTTISUE).seq Camis fupus familiaris(XTTISUE).seq Camis fupus familiaris(XTTISUE).seq Roso asglanz (MMC3586.7).seq Roso asglanz (MMC3586.7).seq Roso asglanz (MMC3586.7).seq Roso Taurus (AY60604.7).seq REDICTED Capita Aircus(XT 0015580.0) REDICTED Macaca memetrina(XM 0117005 REDICTED Macaca memetrina(XM 0111000).seq Camis fupus familiaris(XM 01002020.1).seq Roso asglens(MMC2884.5).seq Roso asglens(MMC2846.5).seq Roso asglens(MMC2846.5).se
GACCCTAI           270           GACCCTAI           GAACCCAI           GAACCCAI           GAAACCAA												ATTOCAAG 3 90 ATTOCAAG	Majority Bos taurus (XY606044.1).seq Camis lupus familiaris(XYT15041).eeq Camis lupus familiaris(XYT15040).eeq Camis lupus familiaris(XYT15040).eeq PREDICTED BubAlus hubAls(XY 06664400. PREDICTED Capra hircus(XY 06564400.). PREDICTED Capra hircus(XY 0656440.).) PREDICTED Macas memetrims(XN 0121055 PREDICTED Macas memetrims(XN 0121055 PREDICTED Capra hircus(XY 01565.1).eeq Camis familiaris(XY 1565.1).eeq Camis familiaris(XY 1565.1).eeq Camis familiaris(XY 1565.1).eeq Camis familiaris(XY 1565.1).eeq Camis familiaris(XY 1565.1).eeq Camis familiaris(XY 1565.1).eeq Camis familiaris(XY 1565.1).eeq PREDICTED bubAlus bubAls(XY 066645.1) PREDICTED familiaris(XY 1565.2).eeq PREDICTED familiaris(

# Fig. 7: Multiple sequence alignment of dog survivin gene with the orthologus sequences using MegAlign DNAstar software

sequences present in the databases such as dog (NM\_001003348.1), dog (AY741504.1), dog (AB095108.1), cat (NM\_001009280.1), horse (XM\_001915400.3), cow (AY606044.1), sheep (XM\_012109576.1), goat (XM\_005694094.1), monkey (XM\_011720054.1), buffalo (XM\_006064105.1), human (HM625836.1), camel (XM\_010983810.1). The comparison of the gene sequences with other species (Fig. 7) revealed that the gene sequence is similar across species with more than 90%

	Percent indentity															
		1	2	3	4	5	6	7	8	9	10	11	12			
Divergence	1		92.6	92.9	92.9	93.6	93.8	93.6	93.1	93.3	93.6	94.3	93.6	1	Bos taurus (AY606044.1).seq	
	2	7.6		99.8	99.8	88.2	82.6	84.5	80.4	84.7	85.5	84.1	85.1	2	Canis familiaris (AY741504.1).seq	
	3	7.6	0.0		100.0	88.4	82.8	84.7	80.6	84.9	85.7	84.3	85.3	3	Canis lupus familiaris (CMT TISSUE).seq	
	4	7.6	0.0	0.0		88.4	82.8	84.7	80.6	84.9	85.7	84.3	85.3	4	Canis lupus familiaris (NM 00100348.1)	
	5	6.8	12.6	12.5	12.5		82.6	86.0	80.8	85.9	86.2	83.5	86.4	5	Felis catus (NM 001009280.1).seq	
	6	6.5	18.4	18.3	18.3	18.7		83.7	80.4	83.3	85.0	97.3	83.9	6	Homo sapiens (HM 625836.1).seq	
	7	6.3	15.9	15.9	15.9	14.1	16.7		82.9	97.9	90.3	84.5	98.4	7	Predicted Bubalus bubalis (XM 006064105.)	
	8	7.3	11.0	11.0	11.0	11.0	13.5	7.6		92.0	90.9	89.2	92.5	8	Predicted Camelus dromedaries (XM 010983)	
	9	6.6	15.5	15.4	15.4	14.2	16.8	1.8	7.9		89.7	84.1	98.4	9	Predicted Caprahiscus (XM 005694094.1)	
	10	6.3	14.4	14.4	14.4	13.6	14.5	10.0	9.1	10.7		85.9	90.1	10	Predicted Equus caballus (XM 001915400.3)	
	11	6.0	16.8	16.7	16.7	17.8	2.8	15.6	11.1	15.7	13.4		84.5	11	Predicted Macaca nemestrina (XM 01172005)	
	12	6.3	15.2	15.1	15.1	13.6	16.2	1.4	7.4	1.2	10.2	15.4		12	Predicted Ovis aries musimon (XM 0121095)	
		1	2	3	4	5	6	7	8	9	10	11	12			

Fig. 8: Percentage identity of dog survivin gene with servivin gene sequence from other species



Fig. 9: Phylogram illustrating the evolutionary relationship of survivin gene of dog (*Canis lupus familiaris*) with sheep (*Ovis aries*), cattle (*Bos taurus*) etc. The phylogenetic tree was constructed using Neighbour-Joining analysis. Numbers represent bootstrap values (given as percentages) for a particular node. Thousand replicates were used in bootstrap analysis for good statistical support. The branch lengths are scaled to represent the relative number of substitutions occurring along each branch

similarity (Fig. 8). The phylogram illustrating the evolutionary relationship of dog survivin gene with the gene sequence from different animal species is shown in Fig. 9.

# DISCUSSION

Dysregulation of cell death pathways occurs in cancer, autoimmune disorders, immunodeficiency diseases and in neuro-degenerative disorders. Thus, proteins involved in apoptosis regulation are attractive therapeutic targets (Deveraux and Reed, 1999). The IAP family proteins are characterized by a novel domain of ~70 amino acids which is named as Baculoviral Iap Repeat (BIR) because of original discovery of these proteins in baculoviruses (Crook *et al.*, 1993; Birnbaum *et al.*, 1994). *Survivin*, a unique member of IAPs is highly over expressed in animal and human cancers (Bongiovanni *et al.*, 2015) and has thus attracted much attention as a target for new oncotherapies. The gene is thoroughly studied in humans and several polymorphisms have been detected in the promoter region of survivin gene. But most of the mutation studies in humans are restricted within the promoter region of survivin gene and to date, there is a single report of

mutation within the coding region of the gene, i.e., lysine>glutamic acid (K129E) mutation in the exon 4 of the protein (Aljaberi et al., 2014). Despite the prevalence of survivin in dog cancers, no studies have been conducted so far in dogs to find out any mutations in the coding region or the promoter region of survivin gene and correlation of such alterations with changes in gene expression in cases of dog cancers. Therefore, the aim of the present study was to analyze the coding region of the survivin gene in cases of CMTs, where the gene expression is highly upregulated. Eight CMT tissues were analyzed for survivin gene over expression and a case of complex mammary carcinoma showing highest (~60 fold) over expression of the gene was selected for sequence analysis of survivin gene coding region. The analysis of the sequence of survivin gene coding region revealed that survivin gene over-expression (in the case under study) is not correlated with any alteration in the gene sequence. Several studies indicate that drastic changes in the expression of cancer related genes are highly correlated with the mutation status of these genes (Masica and Karchin, 2011) but in our study we do not found any correlation in survivin gene over-expression and gene mutation. Further, comparison of the dog survivin gene CDS with other species revealed that the sequence is similar across species with more than 90% similarity. The reasons for similarity in gene sequence could be many, including the conserved nature and abundant expression of the protein in vast majority of cancers. Thus, it can be assumed that the gene is subjected to high selection pressure to maintain its functional conformity. These assumptions are also in line with Behera et al. (2015) who reported that the conserved nature of the hfq gene of S. typhimurium may be due to heavy selection pressure. Other researchers also support that across evolution, the survivin protein is conserved in function as homologues of the protein are found both in vertebrates as well as invertebrates (Tamm et al., 1998). The human survivin protein shares 84 and 91.5% sequence identity with mouse (Li and Altieri, 1999) and canine survivin (Uchide et al., 2005), respectively, indicative of a conserved function of survivin in mammalian species. The ectopic expression of some baculoviral IAPs blocks apoptosis in mammalian cells also suggests conservation of the cell death program among diverse species and similarities in the pathways used by the IAPs to inhibit apoptosis (Deveraux and Reed, 1999).

### CONCLUSION

Survivin gene is over expressed in 75% of canine mammary cancers and real time PCR based assay standardized in this study can be employed for detecting survivin gene over expression in CMT tissues. Further, no correlation was observed between survivin gene over expression and mutation status of the coding region of the gene. The results from the study needs to be further validated in large number of CMT cases.

### ACKNOWLEDGMENTS

The authors are thankful to Director, IVRI and Izatnagar for providing the necessary infrastructure facilities to carry out the research work. Authors are also thankful to Department of Biotechnology (DBT), Govt. of India and Indian Council of Agricultural Research (ICAR) as the study was supported by the grant provided by DBT (Project grant No. BT/PR13900/ADV/ 57/ 44/ 2010) as well as ICAR-NAE programme on biosensors. The Department of Science and Technology (DST) is also highly acknowledged for its financial support in terms of providing INSPIRE fellowship to the first author.

### REFERENCES

- Adida, C., P.L. Crotty, J. McGrath, D. Berrebi, J. Diebold and D.C. Altieri, 1998. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am. J. Pathol., 152: 43-49.
- Aljaberi, A.M., J.R. Webster and S.P. Wheatley, 2014. Analysis of the functional repertoire of a mutant form of survivin, K129E, which has been linked to lung cancer. Cancer Cell Int., Vol. 14.
- Altieri, D.C., 2003. Survivin in apoptosis control and cell cycle regulation in cancer. Prog. Cell Cycle Res., 5: 447-452.
- Altieri, D.C., 2006. Targeted therapy by disabling crossroad signaling networks: The survivin paradigm. Mol. Cancer Ther., 5: 478-482.
- Altieri, D.C., 2008. Survivin, cancer networks and pathway-directed drug discovery. Nat. Rev. Cancer, 8: 61-70.
- Ambrosini, G., C. Adida, G. Sirugo and D.C. Altieri, 1998. Induction of apoptosis and inhibition of cell proliferation by *survivin* gene targeting. J. Biol. Chem., 273: 11177-11182.
- Beck, J., S. Hennecke, K. Bornemann-Kolatzki, H.B. Urnovitz and S. Neumann *et al.*, 2013. Genome aberrations in canine mammary carcinomas and their detection in cell-free plasma DNA. PLoS ONE, Vol. 8. 10.1371/journal.pone.0075485
- Behera, P., M. Kutty, B. Sharma, A. Kumar and M. Saxena, 2015. Cloning and sequencing of *hfq* (host factor required for synthesis of bacteriophage Q beta RNA) gene of *Salmonella* Typhimurium isolated from poultry. Vet. World, 8: 610-614.
- Birnbaum, M.J., R.J. Clem and L.K. Miller, 1994. An apoptosis-inhibiting gene from a nuclear polyhedrosis virus encoding a polypeptide with Cys/His sequence motifs. J. Virol., 68: 2521-2528.
- Blanc-Brude, O.P., M. Mesri, N.R. Wall, J. Plescia, T. Dohi and D.C. Altieri, 2003. Therapeutic targeting of the survivin pathway in cancer: Initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Clin. Cancer Res., 9: 2683-2692.
- Bongiovanni, L., M. Romanucci, D. Malatesta, A. D'Andrea, A. Ciccarelli and L. Della Salda, 2015. Survivin and related proteins in canine mammary tumors: Immunohistochemical expression. Vet. Pathol., 52: 269-275.
- Chang, Q., Z.R. Liu, D.Y. Wang, M. Kumar, Y.B. Chen and R.Y. Qin, 2004. Survivin expression induced by doxorubicin in cholangiocarcinoma. World J. Gastroenterol., 10: 415-418.
- Crook, N.E., R.J. Clem and L.K. Miller, 1993. An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif. J. Virol., 67: 2168-2174.
- Davidson, E.B., 2003. Treatment of mammary tumors in dogs and cats. Proceedings of the North American Veterinary Conference, January 18-22, 2003, Orlando, USA., pp: 1036-1038.
- Deveraux, Q.L. and J.C. Reed, 1999. IAP family proteins-suppressors of apoptosis. Genes Dev., 13: 239-252.
- Egenvall, A., B.N. Bonnett, P. Ohagen, P. Olson, A. Hedhammar and H. von Euler, 2005. Incidence of and survival after mammary tumors in a population of over 80,000 insured female dogs in Sweden from 1995 to 2002. Prev. Vet. Med., 69: 109-127.
- El-Magd, G.H.A., A.S. Mohamed, O.A. El-Fattah and A.A. Elateef, 2012. The utility of survivin mRNA as a diagnostic biomarker in lung cancer with malignant pleural effusion. Egypt. J. Chest Dis. Tuberculosis, 61: 103-108.

- ElSheikh, S.M., T.A. Omar, H.S. Abdel Halim and M.F. AbdelSattar, 2014. Expression of the antiapoptotic survivin in the adenomatoid odontogenic tumors. Tanta Dental J., 11: 174-179.
- Jaiswal, P.K., A. Goel and R.D. Mittal, 2015. Survivin: A molecular biomarker in cancer. Indian J. Med. Res., 141: 389-397.
- Kumar, V., A.K. Abbas and J.C. Aster, 2010. The Breast. In: Robbins' and Cotran's Pathologic Basis of Disease, Kumar, V., A.K. Abbas, J.C. Aster and N. Fausto (Eds.). 8th Edn., Saunders, Philadelphia, ISBN-13: 978-1416031215, pp: 1084-1085.
- Lechler, P., X. Wu, W. Bernhardt, V. Campean and S. Gastiger *et al.*, 2007. The tumor gene survivin is highly expressed in adult renal tubular cells: Implications for a pathophysiological role in the kidney. Am. J. Pathol., 171: 1483-1498.
- Li, F. and D.C. Altieri, 1999. Transcriptional analysis of human *survivin* gene expression. Biochem. J., 344: 305-311.
- MacEwen, E.G. and S.J. Withrow, 1996. Soft Tissue Sarcomas. In: Small Animal Clinical Oncology, Withrow, S.J. and E.G. MacEwen (Eds.). 2nd Edn., W.B. Saunders Co., Philadelphia, pp: 211-226.
- Masica, D.L. and R. Karchin, 2011. Correlation of somatic mutation and expression identifies genes important in human glioblastoma progression and survival. Cancer Res., 71: 4550-4561.
- Misdorp, W., R.W. Else, E. Hellmen and T.P. Lipscomb, 1999. Histological Classification of Mammary Tumors of the Dog and the Cat. 2nd Edn., Armed Forces Institute of Pathology, American Registry of Pathology, World Health Organization Collaborating Center for Worldwide Reference on Comparative Oncology, Washington, DC., ISBN: 1-881041-66-2.
- Murphy, S., 2008. Mammary tumours in dogs and cats. Practice, 30: 334-339.
- Noushmehr, H., D.J. Weisenberger, K. Diefes, H.S. Phillips and K. Pujara *et al.*, 2010. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell, 17: 510-522.
- Pharoah, P.D.P., A.M. Dunning, B.A.J. Ponder and D.F. Easton, 2004. Association studies for finding cancer-susceptibility genetic variants. Nat. Rev. Cancer, 4: 850-860.
- Queiroga, F.L., T. Raposo, M.I. Carvalho, J. Prada and I. Pires, 2011. Canine mammary tumours as a model to study human breast cancer: Most recent findings. *In vivo*, 25: 455-465.
- Rutteman, G.R. and W. Misdorp, 1993. Hormonal background of canine and feline mammary tumours. J. Reprod. Fertil. Suppl., 47: 483-487.
- Salas, Y., A. Marquez, D. Diaz and L. Romero, 2015. Epidemiological study of mammary tumors in female dogs diagnosed during the period 2002-2012: A growing animal health problem. PloS ONE, Vol. 10. 10.1371/journal.pone.0127381
- Schmittgen, T.D. and K.J. Livak, 2008. Analyzing real-time PCR data by the comparative  $C_{\rm T}$  method. Nat. Protocols, 3: 1101-1108.
- Shafiee, R., J. Javanbakht, N. Atyabi, P. Kheradmand and D. Kheradmand *et al.*, 2013. Diagnosis, classification and grading of canine mammary tumours as a model to study human breast cancer: An clinico-cytohistopathological study with environmental factors influencing public health and medicine. Cancer Cell Int., Vol. 13.
- Simon, D., D. Schoenrock, W. Baumgartner and I. Nolte, 2006. Postoperative adjuvant treatment of invasive malignant mammary gland tumors in dogs with doxorubicin and docetaxel. J. Vet. Internal Med., 20: 1184-1190.
- Sleeckx, N., H. de Rooster, E.J.B.V. Kroeze, C. van Ginneken and L. van Brantegem, 2011. Canine mammary tumours, an overview. Reprod. Domestic Anim., 46: 1112-1131.

- Tamm, I., Y. Wang, E. Sausville, D.A. Scudiero, N. Vigna, T. Oltersdorf and J.C. Reed, 1998. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases and anticancer drugs. Cancer Res., 58: 5315-5320.
- Tango, Y., R. Kano, H. Maruyama, K. Asano, S. Tanaka, A. Hasegawa and H. Kamata, 2010. Detection of autoantibodies against survivin in sera from cancer dogs. J. Vet. Med. Sci., 72: 917-920.
- Tao, Y.F., J. Lu, X.J. Du, L.C. Sun and X. Zhao *et al.*, 2012. Survivin selective inhibitor YM155 induce apoptosis in SK-NEP-1 Wilms tumor cells. BMC Cancer, Vol. 12. 10.1186/1471-2407-12-619
- Uchida, H., T. Tanaka, K. Sasaki, K. Kato and H. Dehari *et al.*, 2004. Adenovirus-mediated transfer of siRNA against survivin induced apoptosis and attenuated tumor cell growth *in vitro* and *in vivo*. Mol. Ther., 10: 162 -171.
- Uchide, T., N. Takatsu, Y. Fujimori, U. Fukushima and H. Itoh, 2005. Expression of survivin mRNA in dog tumors. DNA Sequence, 16: 329-334.
- Verhaak, R.G.W., K.A. Hoadley, E. Purdom, V. Wang and Y. Qi *et al.*, 2010. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in *PDGFRA*, *IDH1*, *EGFR* and *NF1*. Cancer Cell, 17: 98-110.
- Wang, X., L. Huang, Y. Xu, Z. Shi and Y. Wang *et al.*, 2012. Association between *survivin* -31G>C promoter polymorphism and cancer risk: A meta-analysis. Eur. J. Hum. Genet., 20: 790-795.
- Xue, J., X.J. Xie and M.F. Lin, 2012. Expression and clinical significance of antiapoptotic gene (Survivin) in NB4 and acute promyelocytic leukemia cells. Scient. World J. 10.1100/2012/937087